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Abstract
Background:  To determine the prevalence and characteristics of diabetic retinopathy (DR)
among Iranian patients with diabetes.
Methods: Design: population-based cross-sectional study.
Participants: patients with diabetes aged 25 to 64 years in Tehran province, Iran. This survey was
conducted from April to October 2007. The study sample was derived from the first national
survey of risk factors for non-communicable disease. Diabetes mellitus was defined as a fasting
plasma glucose of ≥ 7.0 mmol/l (126 mg/dl) or more, use of diabetic medications, or a physician's
diagnosis of diabetes. All patients known to have diabetes underwent an eye examination by bio-
microscope and indirect ophthalmoscope to check for any signs of DR through dilated pupils by +
78 lens. Participants were also interviewed and examined to determine their demographic
characteristics, medical conditions and the regularity of their eye visits.
Results: Among 7989 screened patients, 759 (9.5%) had diabetes. Of them, 639 patients (84.2%)
underwent eye examination. Five patients (0.7%) with media opacity were excluded. Of 634
examined patients with diabetes, 240 had some degree of diabetic retinopathy, and the overall
standardized prevalence of any retinopathy was 37.0% (95% CI: 33.2-40.8), including 27.3% (95%
CI: 23.7-30.8) (n = 175) with non-proliferative and 9.6% (95% CI: 7.3-11.9) (n = 65) with
proliferative diabetic retinopathy. Clinically significant macular edema and vision-threatening
retinopathy were detected in 5.8% (95% CI: 4.0-7.7) (n = 38) and 14.0% (95% CI: 11.3-16.7) (n =
95) of patients, respectively. Only 143 patients (22.6%) with diabetes had a history of regular eye
examination.
Conclusion: This study demonstrated a high prevalence and poor control of DR in Tehran
province. This suggests the need for adequate prevention and treatment in patients with diabetes.
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Background
Diabetes mellitus (DM) is one of the most common non-
communicable diseases with an increasing incidence
worldwide. Recent estimates indicate that there were 171
million people throughout the world living with diabetes
in the year 2000, and this number is projected to increase
to 366 million by 2030, with the most significant increase
occurring in developing countries [1]. While most indi-
viduals affected with DM in developed countries are eld-
erly, the majority of subjects in developing countries are
younger (46-64 years of age), which intensifies the conse-
quences of DM in these societies [2].
The main ocular complications of DM are cataracts and
diabetic retinopathy (DR); the earliest clinical signs of DR
present at different times depending on the diabetes type;
they occur in nearly all subjects who have had type 1 dia-
betes (commonly early onset and due to immune-medi-
ated factors) for 20 years [3] and in nearly 80 percent of
those with type 2 disease (including individuals who are
insulin resistant, obese and middle-aged and have relative
insulin deficiency) with the same duration [4].
DR is increasingly becoming a major cause of blindness
throughout the world; in addition, loss of productivity
and quality of life for the patient with DR will lead to
additional socioeconomic burdens on the community
[5]. However, appropriate treatment can decrease the loss
of vision caused by proliferative DR by up to 90% [6].
The type and duration of diabetes, age, gender, glycemic
control, systemic hypertension, body mass index (BMI),
smoking, serum lipids, and microalbuminuria are associ-
ated with the development and progression of DR [7-10].
According to a recent study in Tehran [11], the prevalence
of DM is much greater than that in industrialized coun-
tries [5] (14% versus 2%) and about one-third of the
patients with diabetes in Tehran [11] and half of those in
Iran [12] are unaware of their illness. Furthermore, a study
conducted in 2004 showed that DR is one of the most
common causes of low vision and blindness in Tehran
province [13]. A study in Isfahan, another large city in
Iran, showed a high incidence of DR among patients with
diabetes using a clinic information system (about 90 per
1000 person-years) [14]. Before the present study, no
information was available on the prevalence of DR in a
population based study in our country [15]; in addition,
there is a lack of information about prevention and con-
trol of DR in Iran. Therefore, this study was conducted to
determine the DR prevalence, characteristics and regular-
ity of eye visits in a representative sample of patients with
DM in Tehran province.
Methods
This cross-sectional study was conducted from April to
October 2007 in Tehran province. The study was
approved by Iranian Center for Disease Control (CDC)
regarding the methodology and ethical considerations. All
investigations were performed according to the guidelines
of the Declaration of Helsinki.
Study sample
The study sample was derived from the first national sur-
vey of risk factors of non-communicable disease (SURF-
NCD) in Iran [12,16], which was performed in January
and February 2005 using the guidelines of the stepwise
approach to non-communicable disease risk factor sur-
veillance of the world health organization [17]. In the
SURFNCD, a multistage probability cluster sampling
scheme was used for random selection of adults through-
out the country. Using a stratified random cluster sam-
pling in Tehran province, proportional to the size of each
district, 9993 citizens were selected from 500 clusters.
Cluster sampling was based on block sampling in urban
areas and family charts in rural areas. In each cluster, after
random selection of the first house as the index, houses
on the right side of the index were selected to fulfill a total
of 20 individuals in each cluster. Five different age groups
(15-24, 25-34, 35-44, 45-55 and 55-64 years old) with
four individuals (2 men and 2 women) in each group
were defined in all clusters. All participants aged 25 to 64
years (7989 persons) were invited to the national diabetes
screening program. Participants who had reported a his-
tory of diabetes diagnosed by a physician or health care
professional were classified as known diabetics. Partici-
pants were asked to go to a specified laboratory for collec-
tion of blood samples, following a 12-hour fast to identify
the undiagnosed patients. Ultimately, 759 patients with
diabetes were defined in Tehran province, of whom 502
(66.1%) had reported a history of known diabetes.
Data collection
Invitation for the current study was sent to all registered
patients with diabetes. Two follow-up notes were sent to
those who failed to respond to the initial invitations; in
addition, all related expenses, including medical evalua-
tion, treatment and transportation were covered by the
research group. Those who did not respond after the third
invitation were considered non-responders.
In the next step, all participants were referred to an oph-
thalmic clinic (Negah Eye Clinic), under supervision of
the Ophthalmic Research Center. Participants were inter-
viewed and examined to determine their demographic
characteristics and medical conditions in addition to their
medications and diet. Required data were collected,
including: sex, age, disease duration, type of diabetes, dys-BMC Ophthalmology 2009, 9:12 http://www.biomedcentral.com/1471-2415/9/12
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lipidemia (based on laboratory findings or use of any
lipid-lowering drugs), and history of diagnosed nephrop-
athy. In addition, two close-ended questions assessed the
regularity of ophthalmic assessment by an ophthalmolo-
gist and the source of information for patients with regu-
lar ophthalmic visits. The term "regular visits" was defined
as the annual ophthalmic examination in accordance with
the definition of American diabetes association.
All patients were examined by a single retina sub-special-
ist who had a five-year work experience in this field and a
good inter-observer agreement with an expert retina sub-
specialist (HA) for diagnosis and grading of DR (both
Kappa values were greater than 0.9). A supervisor team
trained the examiner at the beginning of the study and
evaluated her during the project.
Complete eye examinations were performed for the
patients. Uncorrected and best corrected visual acuities
were determined using Snellen charts and a Topcon
autorefractometer (KR 8000, Topcon, and Tokyo, Japan).
The ophthalmologic evaluation included bio-microscope
examination of the anterior segment, lens opacity,
intraocular pressure measurement using Goldmann
applanation tonometry (Haag-Streit, Bern, Switzerland)
and dilated fundoscopy using a +78-diopter non-contact
fundus viewing lens (Nikon). Finally with examination by
indirect ophthalmoscopy, a full retinal and macular
examination was completed. DR was graded according to
the scale proposed by the American academy of ophthal-
mology [18] based on the more severely affected eye.
Vision-threatening retinopathy was defined as the pres-
ence of severe NPDR, PDF or CSME [19].
Patients with media opacity significant enough to pre-
clude the retinopathy evaluation were excluded from the
analysis. All instruments were regularly calibrated at the
beginning and during the study.
Definitions
Diabetes mellitus was defined as use of diabetic medica-
tion or a physician's diagnosis, or, in those without
known diabetes, it was defined as fasting plasma glucose
≥ 7.0 mmol/l (126 mg/dl) in accordance with the current
WHO diagnostic criteria for diabetes [20]. However, given
that oral glucose tolerance testing (2-h plasma glucose ≥
11.1 mmol/l (200 mg/dl)) was not performed in the orig-
inal survey, we did not include this item in the case defi-
nition. Glycosylated hemoglobin (HbA1c) level was
measured using the Bayer DCA 2000+ analyzer, with val-
ues less than 7% considered to be indicators of good gly-
cemic control.
Blood pressure was measured in the seated position using
standard mercury sphygmomanometers, and hyperten-
sion was defined as a systolic blood pressure of 140
mmHg or more and/or a diastolic blood pressure of 90
mmHg or more; or ongoing treatment with antihyperten-
sive drugs [2]. Hyperlipidemia was defined as total choles-
terol of 6.2 mmol/l or more or the use of lipid-lowering
drugs [21].
Visual impairment was classified based on best corrected
visual acuity (BCVA). Low vision was defined as BCVA less
than 20/60, but equal to or better than 20/400 in the bet-
ter eye, and blindness was defined as visual acuity less
than 20/400 in the better eye based on WHO criteria [22].
Statistical analysis
For descriptive purposes, quantitative variables were pre-
sented as mean ± SD, and qualitative data were reported
in terms of rates and proportions. In addition, age-sex
adjusted prevalence rates and their confidence intervals
(CI) 95% were reported. For analytic purposes, conven-
ient parametric and non-parametric analyses such as Chi-
square, Fisher's exact and Mann-Whitney tests were uti-
lized. To evaluate the simultaneous effect of different risk
factors or risk indicators including age, gender, duration
of diabetes, hypertension, HbA1C, nephropathy, hyperli-
pidemia and method of diabetes control on the presence
of DR (the response variable), a multiple logistic regres-
sion model was used. P-values less than 0.05 were consid-
ered statistically significant. Statistical analysis was
performed using STATA version 8 software.
Results
Among 7989 screened individuals, 759 (9.5%) had diabe-
tes. Of them, 639 eligible patients (a response rate of
84.2%) participated in this study. Five patients (0.7%)
were excluded due to severe corneal or lens opacity pre-
cluding fundus examination. The mean ± SD age of the
634 remaining patients was 58.16 ± 11.98 years.
Ophthalmic examination revealed that 240 subjects had
some degree of DR (age standardized prevalence rate of
37.0%, 95% CI: 33.2-40.8), including 175 patients with
non-proliferative (NPDR) and 65 patients with prolifera-
tive diabetic retinopathy (PDR). Clinically significant
macular edema (CSME) was detected in 38 patients.
Among patients with CSME, 20 patients had NPDR
(11.4% of the NPDR patients), and 18 had PDR (27.7%
of PDR patients). See Table 1 for more detailed informa-
tion about the crude and age-standardized prevalence
rates of different grades of DR and CSME in the patients
with diabetes in this study. The presented P-values in
Table 1 show that there is a significant difference between
male and female patients in age-standardized prevalence
rates of different grades of DR and CSME.
Table 2 shows the frequency distribution and the preva-
lence rate of DR of all grades by different characteristics of
the patients. Univariate statistical tests revealed that thereBMC Ophthalmology 2009, 9:12 http://www.biomedcentral.com/1471-2415/9/12
Page 4 of 8
(page number not for citation purposes)
was a significant relationship between the presence of DR
and patients' age, sex, duration of diabetes, presence of
hypertension and nephropathy, and method of diabetes
control. The P-values presented in the last column of
Table 2 show the results of statistical tests evaluating the
differences between characteristics of male and female
patients with any grade of DR. The only significant P-
value in this column tells us that female patients with DR
had a higher rate of hypertension than males with DR [69
out of 116 women (59.9%) with DR vs. 38 out of 124
men (30.6%) with DR, P < 0.001].
The prevalence of low vision and blindness among 634
participants were 6.5% (95% CI: 4.7-8.7) and 1.6% (95%
CI: 0.8-2.9), respectively. The prevalence of any type of
visual impairment (BCVA < 20/60) in patients with PDR
was remarkably higher than that in patients without PDR
(18.5% vs. 7.0%, P = 0.002, OR = 2.09, 95% CI: 1.02-
4.26).
Among the diabetic patients studied (634 cases), 233
patients (36.8%) had a history of eye examination. Of
them, only 143 patients (22.6%) had a history of regular
eye examination, while 90 patients (14.2%) reported
non-regular ophthalmologist visits. The other 401
patients (63.2%) said that they would have an eye exami-
nation after the occurrence of an ocular symptom. The
prevalence of DR in the above mentioned groups was
18.9%, 30.0% and 46.4% respectively (P < 0.001).
Among patients with regular eye examination (143
patients), 61.1% had been informed to do so by physi-
cians, 17.4% by mass media and 21.5% by other patients
with diabetes.
In the final step, to assess the simultaneous effect of differ-
ent risk factors or risk indicators on the presence of any
DR, a logistic regression model was utilized (Table 3). The
obtained results revealed that males, patients with a
longer history of diabetes, patients using insulin or oral
medication for diabetes control, and patients with hyper-
tension or nephropathy had a statistically significant
increase in risk of any grade of DR as compared to other
subjects.
Discussion
The present study showed that the prevalence of DR in a
representative sample of patients with diabetes in Tehran
in 2007 was 37%. This prevalence is comparable to find-
ings obtained from non-Asian populations [23,24] and
two other major Asian population-based studies in Tai-
wan (35%) [25] and Singapore (35%) [26]. In addition, a
clinic-based study in Oman reported a comparable preva-
lence (42%) [27]. Most of the Asian studies indicated a
much lower prevalence of DR, some of these studies, such
as the Chennai urban rural epidemiology study (CURES)
[28], were population based and used retinal photogra-
Table 1: Prevalence and severity of diabetic retinopathy and macular edema by gender
Total persons with diabetes
(N = 634)
Men with diabetes
(N = 287)
Women with diabetes
(N = 347)
P¶
n Crude† Standardized* n Crude† Standardized* n Crude† Standardized*
Any retinopathy 240 37.9
(34.1-41.6)
37.0
(33.2-40.8)
124 43.2
(37.4-49)
43.9
(38.1-49.6)
116 33.4
(28.4-38.4)
33.1
(28.1-38.0)
0.005
CSME§ 38 6.0
(4.1-7.8)
5.8
(4.0-7.7)
20 6.9
(3.9-9.8)
6.9
(4.0-9.8)
18 5.2
(2.8-7.5)
5.3
(2.9-7.6)
<0.001
VTR§ 95 15
(12.2-17.8)
14.0
(11.3-16.7)
58 20.2
(15.5-24.9)
21.9
(17.1-26.7)
37 10.7
(7.4-13.9)
9.5
(6.4-12.6)
<0.001
Retinopathy Grades
NPDR 175 27.6
(24.1-31.1)
27.3
(23.7-30.8)
85 29.6
(24.3-34.9)
29.3
(24.0-34.6)
90 25.9
(21.3-30.6)
26.2
(21.6-30.9)
<0.001
Mild NPDR 114 17.8
(14.9-20.8)
17.9
(14.9-20.9)
53 18.2
(13.8-22.7)
17.7
(13.3-22.1)
61 17.5
(13.5-21.5)
17.9
(13.9-22.0)
<0.001
Moderate NPDR 42 6.6
(4.6-8.5)
6.6
(4.7-8.6)
20 6.9
(3.9-9.8)
6.4
(3.6-9.2)
22 6.3
(3.8-8.9)
6.7
(4.1-9.4)
0.024
Severe NPDR 19 3
(1.7-4.3)
2.6
(1.4-3.9)
12 4.1
(1.8-6.4)
4.8
(2.3-7.2)
72
(0.5-3.5)
1.4
(0.1-2.6)
<0.001
PDR 65 10.3
(7.9-12.6)
9.6
(7.3-11.9)
39 13.6
(9.6-17.6)
14.5
(10.4-18.6)
26 7.5
(4.7-10.3)
6.8
(4.1-9.5)
<0.001
†Data presented in Crude and Standardized columns are percentages and confidence intervals 95%.
* Age- standardized to the 2006 Tehran population census.
¶ P- Value for difference in prevalence and severity of retinopathy by gender, based on chi-square test.
§CSME: Clinically significant macular edema, VTR: Vision threatening retinopathyBMC Ophthalmology 2009, 9:12 http://www.biomedcentral.com/1471-2415/9/12
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phy which indicated 17.6% and 5.1% DR in known and
newly diagnosed diabetics respectively. Another popula-
tion based study from the United Arab Emirates reported
19% DR prevalence [29]. Some studies used clinical
examinations such as reports from Pakistan and India,
which demonstrated 17.5% and 26.2% DR prevalence
respectively [30,31]. These differences may be due to var-
iations in setting, sample size, limitation in compensation
of confounders and the diagnostic method (imaging vs.
clinical) [32]. However it seems the DR prevalence is
lower in some ethnicities in Asia than it is in Caucasians
[33].
In the current study, men, as compared to women, had
significantly higher prevalence with greater severity of dia-
betic retinopathy in both univariate and multivariate
analysis. A similar male preponderance has been reported
in some studies [[28,29,34] and [35]]. In contrast, other
studies have not shown a consistent pattern of gender var-
iation in DR prevalence [[3,23,26] and [36]] or incidence
[37]. In the Singapore Malay Eye Study, a higher preva-
lence of more severe DR was observed in women; how-
ever, this difference was lost after adjustment for
metabolic and socioeconomic risk factors [26]. More stud-
ies are needed to examine the causes of this inconsistency
of DR prevalence in gender differences in different popu-
lations.
The prevalence of macular edema in our study (5.8%) is
comparable to the findings obtained from previous
reports [26,36]. In addition, the present study confirmed
the correlations found in other studies between risk fac-
tors such as longer duration of diabetes, systemic hyper-
tension and nephropathy and the presence of DR [23-
30,34-39].
Table 2: Participant characteristics by presentation of diabetic retinopathy and gender
Characteristic Total
(N = 634)
No DR
(n = 394)
Any DR
(n = 240)
P* Men with DR
(n = 116)
Women with DR
(n = 124)
P¶
Age (years) 59.29 (11.98) 60.15 (12.50) 55.89 (10.96) 0.017 57.73 (10.56) 58.06 (11.42) 0.814
Sex (%)
Male 287 (45.3) 163 (56.8) 124 (43.2) 0.012 - - -
Female 347 (54.7) 231 (66.6) 116 (33.4)
Diabetes type
I 16 (2.5) 7 (43.8) 9 (56.3) 0.12 3 (42.9)§ 6 (66.7)§ 0.321
II 618 (97.5) 387 (62.6) 231 (37.4) 121 (43.2) 110 (32.5)
Duration (year)
<5 215 (33.9) 167 (77.7) 48 (22.3) <0.001 27 (29.7) 21 (16.9) 0.981
5-10 214 (33.8) 141 (65.9) 73 (34.1) 32 (34.0) 41 (34.2)
11-15 100 (15.8) 54 (0.54) 46 (0.46) 28 (59.6) 18 (34.0)
15-20 47 (7.4) 12 (25.5) 35 (74.5) 19 (86.4) 16 (64.0)
>20 58 (9.1) 20 (34.5) 38 (65.5) 18 (54.5) 20 (80.0)
Hypertension
Absent 383 (60.4) 250 (65.3) 133(34.7) 0.045 86 (42.6) 47 (26.0) <0.001
Present 251 (39.6) 144(57.4) 107 (42.6) 38 (44.7) 69 (41.6)
Nephropathy
Absent 599 (94.5) 380 (63.4) 219 (36.6) 0.005 112 (42.1) 107 (32.1) 0.599
Present 35 (5.5) 14 (40.0) 21 (60.0) 12 (57.1) 9 (64.3)
Hyperlipidemia
Absent 360 (56.8) 232 (64.4) 128(35.6) 0.17 73 (39.9) 55 (31.1) 0.075
Present 278 (43.2) 162(59.1) 112 (40.9) 51 (49.0) 61 (35.9)
HgbA1C
Control 396 (62.5) 252 (63.6) 144 (36.4) 0.318 68 (40.7) 76 (33.2) 0.092
Uncontrol 238 (37.5) 142 (59.7) 96 (40.3) 56 (46.7) 40 (33.9)
Diabetes control
Diet +Exercise 56 (8.8) 55(98.2) 1(1.8) <0.001 0 (0.0) 1 (2.6) 0.319
Oral medication 513 (81.0) 309 (60.2) 204 (39.8) 103 (43.8) 101 (36.3)
Insulin injection 65 (10.2) 30(46.2) 35 (53.8) 21 (61.8) 14 (45.2)
Data presented are means ± standard deviation for age or number (%) for other characteristics.
* P- Value for difference in characteristics by Diabetes Retinopathy (DR) status, based on chi-square test, Fisher's Exact, Mann-Whitney or t-test, as 
appropriate.
¶P- Value for difference in characteristics by gender in patients with DR based on chi-square, Fisher's Exact, Mann-Whitney or t-tests, as 
appropriate.
§Percentages in two columns showing men/women with DR concern the percentage of each characteristic in comparison with men/women without 
DR which are omitted to make the table less crowdedBMC Ophthalmology 2009, 9:12 http://www.biomedcentral.com/1471-2415/9/12
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Recently, a comprehensive systematic review revealed that
tight glycemic control (HbA1c in normal range) reduces
the incidence and progression of DR [38]. In the present
study, the quality of glycemic control did not show any
significant association with DR. This unusual finding may
be a manifestation of a better blood sugar control after the
diagnosis of diabetes through the national survey three
years ago.
Visual impairment and blindness were observed in 8.1%
of our patients; these rates were much higher than the per-
centage seen in the adult population in Iran. A recent
comprehensive population-based study conducted in a
similar setting, age group and using a similar definition
for visual impairment in a normal population in Tehran
province showed a 1.67% prevalence of visual impair-
ment [40]. Furthermore there is a 5.7% estimate for visual
impairment in the eastern Mediterranean region in the
population over 50 years of age [22]. This finding shows
poor screening and management in patients with diabetes
in our population, given that studies have shown that loss
of vision due to diabetes is uncommon in a population
that is carefully screened for diabetes mellitus and pro-
vided with regular eye screening [6,41]. We found a high
preponderance for visual impairment in patients with
PDR which is in line with previous findings [42].
Routine and repetitive clinical retinal examination is
essential for the fundamental ophthalmic care of patients
with diabetes [43]. Retinopathy screening should be per-
formed within three to five years after the onset of type 1
diabetes and shortly after the diagnosis of type 2, with
annual follow-up examinations in both types of diabetes
[44]. In contrast with developed countries [6,41], most of
the patients with diabetes (81.1%) in this study had no
regular follow up program for management of DR and the
prevalence of DR was found to be higher in these patients.
In addition, it should be mentioned that samples of this
study were enrolled from a previous survey which was per-
formed 3 years prior to the current study. During that
study 35% of the patients who were unaware of their dia-
betes at the time were informed about their diseases and
might be told to have regular eye examination. So the real
mismanagement of retinopathy is probably even higher
in society than the results of this study show.
In summary, the present study is the first report of DR
from Iran via a population-based study. By extrapolating
the adjusted prevalence rates, we can estimate that
237000 people out of about 640000 adults with diabetes
in Tehran province have some degree of DR and 14 in 100
adults with diabetes have vision-threatening DR.
There are some limitations in this study that might be
important for interpretation of results. First of all, the
baseline data of non responders (16%) was unavailable;
this could be a potential source of bias. In addition, the
prevalence of nephropathy in our study might be lower
than the true prevalence, as we only determined nephrop-
athy by a history of a previous diagnosis. It should be
mentioned that our definition of hypertension differs
from that of the American physician association from
2007, which defines appropriate blood pressure as less
than 130/80 mmHg in diabetic patients; however, some
of the major population-based surveys [[25,26] and [45]]
defined appropriate blood pressure in patients with dia-
betes as 140/90 mmHg. Only 2.5% of diabetes cases in
this study had type I diabetes mellitus, this limited
number did not allow us to compare type I and type II dia-
betes. Finally, we used clinical examination for diagnosis
and grading of DR. While clinical exam is inexpensive and
widely available, it is not very sensitive when compared
with stereoscopic fundus photography and could limit a
direct comparison with other similar recent studies.
Conclusion
The prevalence of DR in Tehran province was 37%. Signif-
icant risk factors for DR were: male sex, long duration of
diabetes, oral medication or insulin use, presence of sys-
temic hypertension and nephropathy. The results of the
present study show that eye care for many of patients with
diabetes is insufficient. Most of the patients in this study
Table 3: Risk factors for diabetic retinopathy based on logistic 
regression results
OR* 95% CI P
Age (Per 10 yrs) 0.95 0.93-0.96 <0.001
Sex (Male gender) 1.53 1.05-2.23 0.025
Duration (year)
>20 9.75 4.44-21.37 <0.001
15-20 6.99 3.45-14.1 <0.001
11-15 2.60 1.49-4.53 0.001
5-10 1.84 1.18-3.04 0.008
<5 Reference
Hypertension 1.55 1.04-2.29 0.028
Nephropathy 2.05 1.08-3.83 0.04
Hyperlipidemia 1.03 0.71-1.50 0.872
Uncontrolled HgbA1C 1.05 0.71-1.49 0.793
Method of diabetes control
Insulin use 32.71 4.11-259.85 0.001
Oral medication 28.82 3.8-213.69 0.001
Diet+ exercise Reference
* Multivariate odds ratios which are adjusted for age, gender, duration 
of diabetes, hypertension, HbA1C, nephropathy, hyperlipidemia and 
method of diabetes control.BMC Ophthalmology 2009, 9:12 http://www.biomedcentral.com/1471-2415/9/12
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had no regular ophthalmic assessments and the preva-
lence of DR was found to be higher in these patients. In
this context, regular screening in patients with diabetes for
early detection of proliferative retinopathy and increasing
public awareness are highly recommended.
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